Healthcare tech company Privia Health Group (NASDAQ:PRVA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 32.5% year on year to $580.4 million. The company’s full-year revenue guidance of $2.08 billion at the midpoint came in 3.6% above analysts’ estimates. Its non-GAAP profit of $0.29 per share was 33.7% above analysts’ consensus estimates. Is now the time to buy PRVA? Find out in our full research report (it’s free for active Edge members). Privia Health (PRVA) Q3 CY202 ...

OLED provider Universal Display (NASDAQ:OLED) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 13.6% year on year to $139.6 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $675 million at the midpoint. Its GAAP profit of $0.92 per share was 21.3% below analysts’ consensus estimates. Is now the time to buy OLED? Find out in our full research report (it’s free for active Edge members). Universal Display ( ...

Water management company Advanced Drainage Systems (NYSE:WMS) reported Q3 CY2025 results beating Wall Street’s revenue expectations , with sales up 8.7% year on year to $850.4 million. The company expects the full year’s revenue to be around $2.95 billion, close to analysts’ estimates. Its non-GAAP profit of $1.97 per share was 19.8% above analysts’ consensus estimates. Is now the time to buy WMS? Find out in our full research report (it’s free for active Edge members). Advanced Drainage (WMS) Q3 CY2025 ...

WisdomTree’s third quarter results were driven by broad-based asset growth and meaningful net inflows across its global product suite. Management highlighted record assets under management (AUM) of $137.2 billion, with net inflows of $2.2 billion supported by strong demand for European gold and cryptocurrency products. CEO Jonathan Steinberg credited the diversification of asset classes, geographies, and client types as a foundation for the firm’s organic growth, stating, “Our scale, stability and growth i ...

Low-code automation software company Appian (NASDAQ:APPN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.4% year on year to $187 million. Guidance for next quarter’s revenue was better than expected at $189 million at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.32 per share was significantly above analysts’ consensus estimates. Is now the time to buy APPN? Find out in our full research report (it’s free for active Edge members). Appian (APPN) Q3 CY2025 ...

Restaurant company Bloomin’ Brands (NASDAQ:BLMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 10.6% year on year to $928.8 million. Its non-GAAP loss of $0.03 per share was 76% above analysts’ consensus estimates. Is now the time to buy BLMN? Find out in our full research report (it’s free for active Edge members). Bloomin' Brands (BLMN) Q3 CY2025 Highlights: Revenue: $928.8 million vs analyst estimates of $904.8 million (10.6% year-on-year decline, 2.7% beat) Adjusted EPS: ...

Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 14.3% year on year to $250.9 million. Its non-GAAP profit of $0.06 per share was significantly above analysts’ consensus estimates. Is now the time to buy FNKO? Find out in our full research report (it’s free for active Edge members). Funko (FNKO) Q3 CY2025 Highlights: Revenue: $250.9 million vs analyst estimates of $262 million (14.3% year-on-year decline, 4.2% miss) Ad ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q3 CY2025 results exceeding the market’s revenue expectations , with sales up 1.4% year on year to $384 million. The company’s full-year revenue guidance of $1.5 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.27 per share was in line with analysts’ consensus estimates. Is now the time to buy LNTH? Find out in our full research report (it’s free for active Edge members). Lantheus (LNTH) Q3 CY20 ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates. Is now the time to buy BDX? Find out in our full research report (it’s free for active Edge members). BD (BDX) Q3 CY2025 Highlights: Revenue: $5.89 billion vs analyst estimates of $5.91 billion (8.3% year-on-year growth, in line) Adjusted EPS: $3.96 v ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates. Is now the time to buy MRNA? Find out in our full research report (it’s free for active Edge members). Moderna (MRNA) Q3 CY2025 Hig ...